Abiomed (NSDQ:ABMD) is touting a regulatory win for its Impella CP heart pump.
The Danvers, Mass.-based medical device company said it landed 510(k) clearance from the FDA for the percutaneous, catheter-based heart pump, which it says can provide peak flows of 4 liters per minute, about 80% of what a healthy heart can pump.
The Impella CP is intended for "partial circulatory support using an extracorporeal bypass control unit, for periods up to 6 hours. It is also intended to be used to provide partial circulatory support (for periods up to 6 hours) during procedures not requiring cardiopulmonary bypass,” according to a press release.
Sign up to get our free newsletters delivered right to your inbox
Last week, Abiomed shares popped on news that the its Impella 2.5 heart pump beat out intra-aortic balloon pump therapy in supporting heart failure patients undergoing percutaneous coronary intervention.*
Results of the 452-patient trial showed that the next-generation Impella system led to a reduction in adverse events in and out of the hospital and a reduction in repeat vascularization when compared to IABP therapy, according to the report published late last month in the journal Circulation.
ABMD shares were down slightly this morning, trading at $20.91 apiece as of about 10:40 for a 0.4% decline.
*Correction, Sept. 10, 2012: This article originally stated that the Protect II study compared IABP therapy during CABG procedures, rather than with percutaneous coronary interventions. Return to the corrected sentence.